Trials / Completed
CompletedNCT01514851
Phase III Double-blind Comparative Study of BAY77-1931 (Lanthanum Carbonate) With Calcium Carbonate
Phase III Double-blind Comparative Study of BAY 77 1931 (Lanthanum Carbonate) With a Calcium Carbonate in Patients With Hyperphosphatemia Undergoing Hemodialysis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 259 (actual)
- Sponsor
- Bayer · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
To assess the effect on reduction of serum phosphate and the safety of BAY77-1931 (Lanthanum Carbonate) in patients with hyperphosphatemia undergoing hemodialysis in a randomized, double-blind, parallel group study in comparison with Calcium carbonate.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lanthanum carbonate (BAY77-1931) | |
| DRUG | Calcium carbonate |
Timeline
- Start date
- 2006-01-01
- Primary completion
- 2006-05-01
- Completion
- 2006-05-01
- First posted
- 2012-01-23
- Last updated
- 2012-06-08
Locations
31 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT01514851. Inclusion in this directory is not an endorsement.